The phase II KN026-CSP-001 study (NCT05427383) evaluating the efficacy of KN026 in combination with chemotherapy in patients with HER2-positive unresectable advanced or metastatic GC who have failed first-line therapy is ongoing. This evidence concerns the gene ERBB2 and gastric cancer.